OBIO Profile
Orchestra BioMed Holdings, Inc. is a pioneering therapeutic device company specializing in innovative treatments and products for cardiovascular diseases. The company's portfolio includes a range of advanced therapeutic solutions designed to address various aspects of cardiovascular health. Orchestra BioMed is known for its development of cutting-edge technologies aimed at improving patient outcomes and advancing the field of cardiovascular medicine.
One of the company’s key offerings is BackBeat Cardiac Neuromodulation Therapy (CNT), an intelligent bioelectronic treatment designed to manage hypertension. This patented therapy leverages bioelectronic technology to modulate neural pathways and address high blood pressure. Additionally, Orchestra BioMed provides Virtue SAB, a patented drug/device combination product designed to treat artery disease by combining the benefits of a drug with a medical device.
The company also offers FreeHold Retractors, a minimally invasive surgical device solution aimed at enhancing surgical precision and patient recovery. Another significant product is Virtue SEB, a drug-eluting balloon angioplasty system developed for the treatment of coronary artery disease. This system combines drug delivery with balloon angioplasty to improve outcomes for patients with coronary artery blockages.
Orchestra BioMed Holdings, Inc. has established a strategic collaboration with Medtronic to further develop BackBeat CNT as a potential treatment for hypertension, specifically in patients who may require a cardiac pacemaker. This partnership reflects the company’s commitment to advancing its therapeutic technologies and expanding their clinical applications. Headquartered in New Hope, Pennsylvania, Orchestra BioMed continues to drive innovation in cardiovascular care through its diverse and evolving product lineup.
|
